

**Standalone Statement of Assets and Liabilities**

S.No	Particulars	Note No.	As at March 31, 2021
<b>A</b>	<b>ASSETS</b>		<b>Amount in Rs.</b>
	<b>Non-Current Assets</b>		
	(a) Property, Plant and equipment	2	3,51,80,145
	(b) Capital Work in Progress		3,52,98,267
	(c) Investment Property		
	(d) Other Intangible Assets		
	(e) Financial Assets		
	(i) Investments		-
	(ii) Other financial assets	3	83,576
	(f) Deferred Tax Assets		
	(g) Other Non-Current Assets	4	10,00,000
	<b>Total non-Current Assets</b>		<b>7,15,61,988</b>
	<b>Current Assets</b>		
	(a) Inventories		-
	(b) Financial Assets		
	(i) Other Investments		-
	(ii) Trade Receivables		-
	(iii) Cash and Cash Equivalents	5	27,497
	(iv) Bank balances other than (iii) above	6	1,50,00,000
	(v) Loans		-
	(v) Other Financial assets		-
	(c) Current tax assets (Net)		-
	(d) Other current Assets	7	90,34,398
	<b>Total Current Assets</b>		<b>2,40,61,895</b>
	<b>TOTAL ASSETS</b>		<b>9,56,23,883</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	(a) Equity Share Capital	8	1,00,000
	(b) Other Equity	9	-3,48,506
	(c) Money Received against Share warrants		
	<b>Total Equity</b>		<b>-2,48,506</b>
	<b>Liabilities</b>		
	<b>Non-Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings		-
	(ii) Other Financial Liabilities	10	9,17,47,643
	(b) Deferred Tax Liabilities		
	(c) Provisions		-
	(d) Other Non-Current liabilities		
	<b>Total Non-Current Liabilities</b>		<b>9,17,47,643</b>
	<b>Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings		-
	(ii) Trade Payables		
	Dues of micro enterprises and small enterprises	11	-
	Dues of creditors other than micro enterprises and small enterprises	11	27,01,996
	(iii) Other Financial Liabilities	12	9,13,059
	(b) Provisions		-
	(c) Other Current Liabilities	13	5,09,691
	<b>Total Current Liabilities</b>		<b>41,24,746</b>
	<b>Total Liabilities</b>		<b>9,58,72,389</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>		<b>9,56,23,883</b>

The accompanying notes are an integral part of these financial Statements

In terms of our report attached

**For P.Chandrasekar LLP**  
 Chartered Accountants  
 FRN : 000580S/S200066

*D. Manikumar*  
 D. Manikumar  
 Partner  
 Membership No 212544

Place: Bengaluru  
 Date: 31/05/2021

For and on behalf of the Board

*Sunil L. Mundra*  
 Sunil L. Mundra  
 Director  
 DIN:00214304

*Sushil Kumar Mundra*  
 Sushil Kumar Mundra  
 Director  
 DIN:214332

**NATURAL BIOGENEX PRIVATE LIMITED**

TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011  
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: U24239KA2020PTC137602

**AUDITED STANDALONE FINANCIAL RESULTS FOR THE PERIOD ENDED 31ST MARCH ,2021**

S.No	Particulars	Note No.	For the Period ended March 31, 2021
			<b>Amount in Rs</b>
I	Revenue from Operations	14	-
II	Other Income	15	24,658
III	<b>Total Income (I+II)</b>		<b>24,658</b>
IV	<b>Expenses:</b>		
	Cost of materials consumed		-
	Changes in Inventories of finished goods, work-in-progress and stock in trade		0
	Employee benefit expense		-
	Finance costs		-
	Depreciation and amortisation expense		-
	Other expenses	16	3,73,164
	<b>Total Expenses (IV)</b>		<b>3,73,164</b>
V	<b>Profit before exceptional items and Tax (III-IV)</b>		<b>-3,48,506</b>
VI	<b>Exceptional Items - Income /( Expenses )</b>		0
VII	<b>Profit before Tax (V - VI)</b>		<b>-3,48,506</b>
VIII	<b>Tax Expense:</b>		
	1) Current tax		
	2) Tax for earlier		
	3) Deferred tax		
	<b>Total Tax expenses</b>		-
IX	<b>Profit for the year (VII-VIII)</b>		<b>-3,48,506</b>
	<b>Other Comprehensive Income</b>		
	A. i) Items that will not be reclassified to profit or loss		
	a) Re-measurement of the defined benefit plan		
	b) Equity instruments through other comprehensive income		
	ii) Income tax relating to items that will not be re-classified to profit or loss		
	B. i) Items that will be reclassified to profit or loss		
	B. i) Items that will be reclassified to profit or loss		
	ii) Income tax relating to items that will be re-classified to profit or loss		
	B. i) Items that will be reclassified to profit or loss		
X	<b>Total other comprehensive income (A(i-ii)+(B(i-ii))</b>		
XI	<b>Total Comprehensive Income (IX+X)</b>		<b>-3,48,506</b>
XII	<b>Earnings Per Equity Share (Nominal value per share Rs.10/-)</b>		
	(a) Basic		<b>-34.85</b>
	(b) Diluted		<b>-34.85</b>

The accompanying notes are an integral part of these financial statements

In terms of our report attached

For P.Chandrasekar LLP  
Chartered Accountants  
FRN.: 000580S/S200066

D. Manikumar

D. Manikumar  
Partner  
Membership No.212544



Place: Bengaluru  
Date: 31/05/2021

For and on behalf of the Board

Sunil L Mundra  
Managing Director  
DIN:00214304

Sushil Kumar Mundra  
Director  
DIN:214332

**NATURAL BIOGENEX PRIVATE LIMITED**

**Statement of Changes in Equity Share Capital and Other Equity for the Period ended 31st March 2021**

Reserves and Surplus	Share Capital	Securities Premium	Retained earnings	Items of other comprehensive income			Total
				Equity Instruments through other Comprehensive income	Actuarial Gain / Loss	Others (specify)	
<b>Balance at March 31,2020</b>							
share allotment	1,00,000	-					1,00,000
Profit for the period			(3,48,506)				-3,48,506
Payment of Dividend and Dividend Distribution Tax							
<b>Balance at March 31,2021</b>	<b>1,00,000</b>	<b>-</b>	<b>-3,48,506</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-2,48,506</b>

The accompanying notes are an integral part of these financial statements

In terms of our report attached

**For P.Chandrasekar LLP**  
Chartered Accountants  
FRN.: 000580S/S200066

*P. Mani Khan*  
D. Manikumar  
Partner  
Membership No.212544



**For and on behalf of the Board**

*Sunil L. Muntra*  
Director  
DIN:00214304

*Sushil Kumar Muntra*  
Director  
DIN:214332

Place: Bengaluru  
Date: 31/05/2021

**NATURAL BIOGENEX PRIVATE LIMITED**  
Notes forming part of the Financial Statements

**NOTE 2**

**PROPERTY, PLANT AND EQUIPMENT AND CAPITAL WORK-IN-PROGRESS**

Particulars	As at March 2021
Carrying amounts of:	
Freehold land	-
Lease Hold Land	3,51,80,145
<b>Total</b>	<b>3,51,80,145</b>
Capital work-in-progress	3,52,98,267
	<b>7,04,78,412</b>

Particulars	Lease Hold Land	Office Equipment	Total
Balance at March 31 2020			-
Additions	3,51,80,145		<b>3,51,80,145</b>
Disposals			-
<b>Balance at March 31 2021</b>	<b>3,51,80,145</b>	-	<b>3,51,80,145</b>

Particulars	Lease Hold Land	Office Equipment	Total
Accumulated depreciation and impairment			-
Balance at March 2020			-
Disposals			-
Depreciation expenses			-
<b>Balance at March 2021</b>	-	-	-
Carrying amount as on Mar 31,2020	-	-	-
<b>Carrying amount as on March 31,2021</b>	<b>3,51,80,145</b>	-	<b>3,51,80,145</b>

**INTANGIBLE ASSETS**

Particulars
Cost or Deemed cost
Balance at March 31, 2020
Additions
Disposals
<b>Balance at March 31, 2021</b>

**INTANGIBLE ASSETS**

Particulars
Accumulated depreciation and impairment
Balance at March 31, 2020
Additions
Disposals
<b>Balance at March 31, 2021</b>
Carrying amount as on March 31,2020
<b>Carrying amount as on March 31,2021</b>



*[Handwritten signature]*

*[Handwritten signature]*

**NATURAL BIOGENEX PRIVATE LIMITED**  
Notes forming part of the Financial Statements

**NOTE 3**

**OTHER FINANCIAL ASSETS - Non Current**

Particulars	As at March 31, 2021
<b>At Amortized Cost</b>	
a) Security Deposit (Unsecured considered good)	58,918
b) Prepaid Rent deposit	
c) Term Deposit	
d) Dividend from Associate /Subsidiary	
Less: Provision for Doubtful advances	
e) Interest Receivable On Deposits	
Secured, Considered good	24,658
<b>Total</b>	<b>83,576</b>

**NOTE 4**

**OTHER ASSETS - NON CURRENT**

Particulars	As at March 31, 2021
a) Security Deposit	
b) Capital Advances	
(i) Secured, Considered good	
(ii) Unsecured and Considered good	10,00,000
(iii) Considered doubtful	
Less: Allowance for doubtful debts (Expected Credit Loss)	
e) Export incentive receivable	
f) Balance with Customs and Central excise / GST authorities	
<b>Total</b>	<b>10,00,000</b>

**NOTE 5**

**CASH AND CASH EQUIVALENTS**

Particulars	As at March 31, 2021
a) Balances with banks	
(i) In Current account	27,497
(ii) In Deposit account with original maturity less than 3 Months	
(ii) In EEFC account	
b) Cash on hand	
c) Cheques,drafts on hand	
<b>Total</b>	<b>27,497</b>



*[Handwritten signature]*

*[Handwritten signature]*

NATURAL BIOGENEX PRIVATE LIMITED  
Notes forming part of the Financial Statements

NOTE 6

OTHER BANK BALANCES

Particulars	As at March 31, 2021
a) Deposit Accounts	1,50,00,000
b) Earmarked Balances with banks	
(i) In unpaid Dividend account	
(ii) In margin money accounts for Bank Guarantee issued	
<b>Total</b>	<b>1,50,00,000</b>

NOTE 7

OTHER CURRENT ASSETS

Particulars	As at March 31, 2021
a) Security Deposit	
b) Capital Advances	
c) Advances to Employees	
(i) Secured, Considered good	
(ii) Unsecured and Considered good	42,000
(iii) Considered doubtful	
Less: Allowance for doubtful debts (Expected Credit Loss)	
e) Export incentive receivable	
f) Balance with Customs and Central excise / GST authorities	2,68,049
g) Advance to suppliers	
(i) Secured, Considered good	
(ii) Unsecured and Considered good	32,24,379
(iii) Considered doubtful	
Less: Allowance for doubtful debts (Expected Credit Loss)	
h) Prepaid Expenses	
i) Preliminary -Pre Operative Expenses	54,99,971
j) Other Advances	
Less: Provision for Doubtful advances	
<b>Total</b>	<b>90,34,398</b>



*[Handwritten signature]*

*[Handwritten signature]*

**NATURAL BIOGENEX PRIVATE LIMITED**  
**Notes forming part of the Financial Statements**

**NOTE 9**

**OTHER EQUITY**

Particulars	As at March 31, 2021
Capital Reserve	
Securities Premium Account:	
General Reserve	
Investments in equity / MF through FVTPL	
Revenue arising from Interest free rental deposit	
Effective interest rate	
Deferred tax adjustment	
Reserve for equity instruments through other comprehensive income	
Actuarial movement through other comprehensive income (net of tax)	
Retained earnings (surplus in profit or loss account)	-3,48,506
<b>Total</b>	<b>-3,48,506</b>

**Note:**

i) Capital reserve: on account of forfeiture of amount paid on convertible shares warrants allotted to non promoters share holders.

ii) Securities Premium reserve: The amount received in excess of Face value of the equity shares is recognised as securities premium reserve.

provisions of Companies Act, 1956. mandatory transfer to general reserve is not required under the Companies Act, 2013

Particulars	As at March 31, 2021
<b>a) Retained Earnings</b>	
Opening balance	-
Profit /(Loss) for the year	-3,48,506
Less: Transfer to Capital Redemption Reserve	-
Less: Dividend on Equity Shares	0
Less: Tax on Dividend on Equity Shares	
Less: Transfer to Reserves	
Less: IND AS Adjustment	
<b>Closing Balance</b>	<b>-3,48,506</b>
The amount that can be distributed by the Company as dividends to its equity shareholders is determined based on the separate financial statements of the Company and also considering the requirements of the Companies Act, 2013. Thus, the amounts reported above are not distributable in entirety.	
<b>Total Other Equity</b>	<b>-3,48,506</b>



NOTE 8

EQUITY SHARE CAPITAL

Particulars	As at March 2021
<b>AUTHORISED</b>	
Equity Shares:	
10000000 Equity shares of Rs.10 each	10,00,00,000
<b>ISSUED, SUBSCRIBED AND FULLY PAID UP</b>	
10,000 Equity Shares of Rs 10/- each	1,00,000
<b>Total</b>	<b>1,00,000</b>

8.1 Reconciliation of number of shares and amount outstanding at the beginning and at the end of the reporting period.

Reconciliation	2020-21 No. of shares	Amount in Rs
a) Equity Shares of Rs.10 each fully paid up		
At the beginning of the period	-	-
Issued during the period	10,000	1,00,000
At the end of the period	10,000	1,00,000
b) Redeemable Preference Share Capital (0%)		
At the end of the period	-	-

8.2 Details of shares held by each shareholder holding more than 5 percent of equity shares in the Company:

Reconciliation	No. of shares held as at	
	March 31, 2021	
Natural Capsules Limited	10,000	100%

8.3 Term attached to Equity Shares:

The Company has one class of equity share having a par value of Rs.10 per share. Each holder of equity share is entitled to one vote per share. The dividend when proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General meeting. Repayment of capital on liquidation will be in proportion to the number of equity shares held.

The Company has not issued any equity shares under ESOP (Employee Stock Option).



Handwritten signatures in blue ink, including a large signature and a smaller one to the right.



**NATURAL BIOGENEX PRIVATE LIMITED**  
Notes forming part of the Financial Statements

**NOTE 10**

**OTHER FINANCIAL LIABILITIES - NON CURRENT**

Particulars	As at	March 31, 2021
<b>At Amortised Cost</b>		
Advance from Customers		
Deposit/ Retention		
Other payable - Holding Company		9,17,47,643
<b>Total</b>		<b>9,17,47,643</b>

**NOTE 11**

**TRADE PAYABLES**

Particulars	As at	March 31, 2021
Dues of Micro Enterprises and Small Enterprises		
Dues of creditors other than micro enterprises and small enterprises		25,18,943
Employee related		1,83,053
<b>Total</b>		<b>27,01,996</b>

Trade payables are non-interest bearing are normally settled between 30-60 days

The Company has requested its suppliers to confirm the status as to whether they are covered under the Micro, Small and Medium Enterprises Development Act, 2006. In the absence of confirmations from the suppliers, disclosure, if any, relating to unpaid amounts as at the year end together with interest paid / payable as required under the Act has not been given.

**NOTE 12**

**OTHER FINANCIAL LIABILITIES - CURRENT**

Particulars	As at	March 31, 2021
<b>At Amortised Cost</b>		
a) Current maturities of long-term debt		
b) Other Liabilities		
Lease Rent Payable		
Payable for capital Goods Purchased		
-Other liabilities (refer Note below)		9,13,059
<b>Total</b>		<b>9,13,059</b>

**NOTE 13**

**OTHER CURRENT LIABILITIES**

Particulars	As at	March 31, 2021
a) Statutory remittances (Contributions to PF, ESIC, TDS, GST, VAT, Service tax etc.)		4,88,421
b) Advances and Deposits from Customers / others		
c) Related to expenses		21,270
<b>Total</b>		<b>5,09,691</b>



*[Handwritten signature]*

*[Handwritten signature]*

NATURAL BIOGENEX PRIVATE LIMITED  
Notes forming part of the Financial Statements

NOTE 14

REVENUE FROM OPERATIONS

Particulars	Year Ended March 31, 2021
(a) Sale of Products	
(b) Other operating revenues	
<b>Total</b>	-

NOTE 15

OTHER INCOME

Particulars	Year Ended March 31, 2021
(a) Interest income	
On Bank Deposits	24,658.00
On other deposits	
Miscellaneous income	
<b>Total</b>	<b>24,658</b>

NOTE 16

OTHER EXPENSES

Particulars	Year Ended March 31, 2021
Auditor's Remuneration	25,000
Travelling Expenses - Foreign	
Travelling and Conveyance	3,19,785
Professional Fees	
Miscellaneous Expenses	28,379
Loss on Sale of Fixed Assets	
<b>Total</b>	<b>3,73,164</b>

NOTE 17

PAYMENT TO AUDITORS

Particulars	
a) Audit Fees	25000
b) Fees for other services	-
<b>Total</b>	<b>25000</b>



*[Handwritten signature]*

*[Handwritten signature]*

**NATURAL BIOGENEX PRIVATE LIMITED**  
Notes forming part of the Financial Statements

Fair value of financial assets and financial liabilities that are not measured at fair value (but fair value disclosures are required)

Particulars	Fair value hierarchy	As at March 31, 2021	
		Carrying amount	Fair value
<b>Financial Assets</b>			
Financial assets at amortised cost:			
Trade receivables	Level 3	-	-
Cash and cash equivalents	Level 2	27,497	27,497
Bank balances other than cash and cash equivalents	Level 2	1,50,00,000	1,50,00,000
Other financial assets	Level 3	83,576	83,576

Particulars	Fair value hierarchy	As at March 31, 2021	
		Carrying amount	Fair value
<b>Financial Liabilities</b>			
Financial liabilities at amortised cost:			
Borrowings	Level 2	-	-
Trade payables	Level 3	27,01,996	27,01,996
Other financial liabilities	Level 3	9,26,60,702	9,26,60,702

**Fair value hierarchy**

The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable and consist of the following three levels:

- Level 1 — Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 — Inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3 — Inputs are not based on observable market data (unobservable inputs). Fair values are determined in whole or in part using a valuation model based on assumptions that are neither supported by prices from observable current market transactions in the same instrument nor are they based on available market data.

1. In case of trade receivables, cash and cash equivalents, trade payables, short term borrowings and other financial assets and liabilities it is assessed that the fair values approximate their carrying amounts largely due to the short-term maturities of these instruments

2. The fair values of the financial assets and financial liabilities included above have been determined in accordance with generally accepted pricing models based on a discounted cash flow analysis, with the most significant inputs being the discount rate that reflects the credit risk of counterparties.



**NATURAL BIOGENEX PRIVATE LIMITED**  
**Notes to the financial statements**

**19 Segment information**

The Company's business comprises the Manufacture Of Chemicals And Chemical Products represents one business segment. Further, the Company has not yet commenced its commercial production.. Consequently, the disclosure of business and geographic segment- wise information is not applicable to the Company.

**20 Capital management**

For the purpose of the Company's capital management, capital includes issued capital, additional paid in capital and all other equity reserves attributable to the equity holders of the parent. The primary objective of the Company's capital management is to maximise the shareholder value.

In order to achieve this overall objective, the company's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans and borrowings. There have been no breaches in the financial covenants of any interest-bearing loans and borrowing in the current period.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The Company includes within net debt, interest bearing loans and borrowings, less cash.

Particulars	₹	
	As at 31-Mar-21	As at 31-Mar-20
Long term borrowings	-	-
Current maturities of long term borrowings	-	-
Short term borrowings	9,17,47,643	-
Less: Cash and cash equivalents	(27,497)	
Less: Balances with Bank	(1,50,00,000)	
<b>Net debt</b>	<b>7,67,20,146</b>	-
Equity	1,00,000	
Other Equity	(3,48,506)	
<b>Total capital</b>	<b>(2,48,506)</b>	
<b>Capital and net debt</b>	<b>7,64,71,640</b>	
<b>Gearing ratio</b>	<b>100.32%</b>	



*[Handwritten signature]*

*[Handwritten signature]*

**NATURAL BIOGENEX PRIVATE LIMITED**  
Notes forming part of the Financial Statements

**NOTE 21**

Note (i) - Related Party Disclosures:

	2020-2021
<b>Related Party Transactions</b>	
<b>Description of Relationship :</b>	
<b>Key Management Personnel - Director</b>	Mr. Sunil Laxminarayana Mundra -Director Mr . Sushil Kumar mundra
<b>Holding company</b>	NATURAL CAPSULES LIMITED
<b>Details of Transactions</b>	<b>Amount in Rs.</b>
<b>NATURAL CAPSULES LIMITED</b>	
Purchase of Leasehold Land	3,51,80,145
Advance Received,	5,65,67,498
Allotment of Equity Shares	1,00,000
<b>Balances outstanding at the end of the year</b>	
<b>Payables</b>	
<b>NATURAL CAPSULES LIMITED</b>	<b>9,17,47,643</b>

**NOTE 22**

This is the first year of incorporation of the company, hence there is no previous years figures for comparison and the period of accounts for the year 2020-2021 is from 23rd Aug 2020 to March 2021

**For P.Chandrasekar LLP**

Chartered Accountants  
FRN.: 000580S/S200066

*D. Mani Kumar*

D. Manikumar  
Partner  
Membership No.212544



Sunil L Mundra  
Director  
DIN:00214304

*Sunil L Mundra*

Sushil Kumar Mundra  
Director  
DIN:214332

*Sushil Kumar Mundra*

Place: Bengaluru  
Date: 31/05/2021